peopleimages / iStockphoto.com
23 February 2018Americas
Takeda makes waves with neurological collaboration
Japan-based Takeda Pharmaceuticals has entered into a global strategic collaboration with Wave Life Sciences.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Asia
29 August 2017 AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.
Asia-Pacific
3 April 2018 Japan-based Takeda has revealed that it is considering plans to acquire biopharmaceutical company Shire.
Editor's picks
Editor's picks
Asia
29 August 2017 AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.
Asia-Pacific
3 April 2018 Japan-based Takeda has revealed that it is considering plans to acquire biopharmaceutical company Shire.
Asia
29 August 2017 AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.
Asia-Pacific
3 April 2018 Japan-based Takeda has revealed that it is considering plans to acquire biopharmaceutical company Shire.